Catalyst Crew Transforms Into AI-Driven Digital Health Company

The latest announcement is out from Catalyst Crew Technologies ( (CCTC) ).

On February 17, 2026, Catalyst Crew Technologies Corp. completed a related-party acquisition of AI-enabled healthcare analytics and telehealth coordination assets from its sole director and executive officer, Kevin Rodan Levy, paying with 12 million restricted common shares and assuming no liabilities. The deal is deemed material, expanded the company’s outstanding common stock to 56.3 million shares, ended its shell-company status, and repositioned it as a development-stage digital health and AI healthcare analytics player focused on Latin America, though it remains pre-revenue, highly capital-constrained, and subject to substantial execution, regulatory and competitive risks.

The acquired intellectual property, including proprietary software and Venezuelan patents for CardioAI, PulmoAI and NeuroAI modules, will form the basis of Catalyst Crew’s AI decision-support platform and integrated telehealth and hybrid care coordination model. However, the company has not obtained regulatory clearances, has no clinical validation, no employees beyond Dr. Levy, and faces significant going-concern doubts, with majority control concentrated in Dr. Levy following his separate purchase of 28 million shares in a change-of-control transaction completed on February 17, 2026.

More about Catalyst Crew Technologies

Catalyst Crew Technologies Corp., formerly a shell company, is a Nevada-based development-stage digital health technology firm focused on artificial intelligence-driven healthcare analytics and technology-enabled medical service platforms. The company plans to offer a modular AI clinical decision-support system and a telehealth and hybrid home-care coordination infrastructure, initially targeting Latin American markets such as Venezuela and prospective expansion into Colombia.

Its AI platform, including disease-focused modules CardioAI, PulmoAI and NeuroAI, is designed to support predictive risk modeling and imaging analysis, while its telehealth layer aims to integrate virtual consultations with coordinated in-person services via third-party providers. Catalyst Crew currently has no revenue, no employees beyond its sole officer and director, limited cash resources, and Venezuelan-only patent protection, leaving it dependent on future capital raises, regulatory approvals and commercial adoption in a highly competitive and heavily regulated digital health landscape.

Average Trading Volume: 769

Technical Sentiment Signal: Sell

Current Market Cap: $19.09M

For detailed information about CCTC stock, go to TipRanks’ Stock Analysis page.